MTOR and plasma cell myeloma: Interactions with stromal cells produce cytokines like IL-6, VEGF, and IGF-1 which activate the PI3K/AKT/mTOR pathway in multiple myeloma patients, initiating a signaling cascade which promotes resistance to chemotherapy and cancerous progression (25, 26).